Publications by authors named "V Ganju"
Bispecific antibodies (BsAbs) combining simultaneous PD-L1 blockade and conditional co-stimulatory receptor activation have been developed to improve immune checkpoint therapy response. However, several PD-L1-based BsAbs have encountered clinical challenges, including insufficient activity or unexpected toxicity. In this study, we propose OX40 as a more suitable target partner for PD-L1-based BsAb design compared to ongoing clinical partners (CD27 and 4-1BB).
View Article and Find Full Text PDFSmall cell lung cancer (SCLC) is an aggressive neuroendocrine tumor characterized by a high metastatic potential with an overall survival rate of ~5%. The transcription factor signal transducer and activator of transcription 3 (STAT3) is overexpressed by >50% of tumors, including SCLC, but its role in SCLC development and metastasis is unclear. Here, we show that, while STAT3 deletion restricts primary tumor growth, it paradoxically enhances metastatic spread by promoting immune evasion.
View Article and Find Full Text PDFPurpose: SHR-A1811 is an antibody-drug conjugate composed of an anti-human epidermal growth factor receptor 2 (HER2) antibody trastuzumab, a cleavable linker, and a topoisomerase I inhibitor payload. We assessed the safety, tolerability, antitumor activity, and pharmacokinetics of SHR-A1811 in heavily pretreated HER2-expressing or mutated advanced solid tumors.
Methods: This global, multi-center, first-in-human, phase I trial was conducted at 33 centers.
Article Synopsis
- The study evaluated a new EGFR-targeted drug, E-EDV-D682/GC, in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had no other treatment options.
- Conducted as a phase I/IIa clinical trial, it focused on safety and overall survival, showing that most patients experienced only mild side effects and there were no serious safety concerns.
- The median overall survival was 4.4 months for all patients, but those who completed a treatment cycle had a better outcome of 6.9 months, indicating potential effectiveness of the treatment.
Background: Initial TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with a BRCA1 or BRCA2 (BRCA) or other DNA damage repair (DDR) gene alteration.
Objective: To present the final data from TRITON2.
Design, Setting, And Participants: TRITON2 enrolled patients with mCRPC who had progressed on one or two lines of next-generation androgen receptor-directed therapy and one taxane-based chemotherapy.